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VA with an average increase of 0.2 lines to a mean VA of 0.72 
 8 0.30 logMAR (p = 0.948) following 3 intravitreal injections 
of bevacizumab. Comparing the effect on VA between both 
groups no statistically significant difference (p = 0.115) was 
noted. Concerning decrease in central retinal thickness both 
therapies were highly effective (p  ! 0.001 each), again, with-
out statistically significant difference between the groups
(p  ! 0.128).  Conclusion: Our data suggest that a single tri-
amcinolone injection may be as effective as a 3 times re-
peated intravitreal administration of bevacizumab for the 
treatment of diabetic macular edema. Further prospective 
trials should be performed.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Diabetic retinopathy remains the major threat to sight 
in the working age population in the developed world. 
Furthermore, it is increasing as a major cause of blind-
ness in other parts of the world, especially developing 
countries  [1] . Diabetic macular edema is a manifestation 
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 Abstract 
 Background: Our purpose was to compare the effect of tri-
amcinolone and bevacizumab (Avastin) on the retinal thick-
ness and functional outcome in patients with diabetic macu-
lar edema.  Methods and Materials: A collective of 32 pa-
tients, who had been treated by a single 4.0-mg intravitreal 
triamcinolone injection (group 1), was matched to 32 pa-
tients (‘matched pairs’), who had received 3 injections of 1.25 
mg of bevacizumab within 3 months in 4-week intervals 
(group 2). The outcome variables were changes in best cor-
rected visual acuity (VA) and central retinal thickness 3 
months after therapy.  Results: Both groups did not differ re-
garding preoperative VA and central retinal thickness mea-
sured by optical coherence tomography. The baseline mean 
VA was 0.72  8 0.39 logMAR in group 1 and 0.73  8 0.39 log-
MAR in group 2 (p = 0.709). The mean central retinal thick-
ness measured by optical coherence tomography was 548 
 8 185   m in group 1 and 507  8 192   m in group 2. While 
the patients in group 1 experienced a slight increase in VA of 
on average 0.7 lines following a single triamcinolone injec-
tion to a mean of 0.64  8 0.40 logMAR (p  =  0.066) after 3 
months, the patients in group 2 showed almost no effect on 
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of diabetic retinopathy that accounts for the loss of cen-
tral vision. Macular edema within 1 disc diameter of the 
fovea is present in 9% of the diabetic population. Al-
though visual loss secondary to proliferative changes is 
more common in patients with type 1 diabetes, visual loss 
in patients with type 2 diabetes is more commonly due to 
macular edema. The development of diabetic retinopathy 
is a multifactorial process. Much of the retinal damage 
that characterizes the disease is now understood to result 
from retinal vascular leakage and nonperfusion mediat-
ed by numerous growth factors such as vascular endothe-
lial growth factor (VEGF)  [2, 3] . Diabetic macular edema 
is caused by excessive vascular permeability, resulting
in the leakage of fluid and plasma constituents, such as 
lipoproteins, into the retina, leading to its thickening. 
Therefore, drugs that counteract these mechanisms seem 
to be potential treatment options, such as steroids (e.g. 
triamcinolone) and anti-VEGF (e.g. bevacizumab) sub-
stances. Especially triamcinolone has been reported to 
effectively reduce the retinal thickness and increase the 
visual acuity (VA) in patients with diabetic macular ede-
ma  [4] . Recently, bevacizumab has been introduced as a 
potential new drug in ophthalmology to successfully 
treat vascular diseases including age-related macular de-
generation, retinal vein occlusion and diabetic macular 
edema  [5–8] . The present study was performed to com-
pare the effect of a single intravitreal injection of 4 mg of 
triamcinolone versus 3 consecutive monthly intravitreal 
injections of 1.25 mg of bevacizumab.
 Methods 
 The present study was designed as a retrospective evaluation 
comparing 32 patients treated with a single intravitreal injection 
of triamcinolone (4.0 mg; group 1) versus 32 patients treated with 
3 consecutive monthly intravitreal injections of bevacizumab 
(1.25 mg; group 2). The individuals for both groups were selected 
randomly from our database while being matched according to 
age, baseline VA and extent of central macular thickness mea-
sured by optical coherence tomography (OCT). The database in-
cludes a predefined data set of all patients being treated for macu-
lar diseases. The collected data comprise age, gender, best cor-
rected VA, intraocular pressure (IOP; Goldmann tonometry), 
central retinal thickness (CRT) measurements by OCT III (Zeiss 
Stratus) and ophthalmic diagnosis. The 3-year data pool in May 
2008 consisted of 2,433 patients. None of them had received a 
therapy for diffuse macular edema within a period of 6 months 
prior to either the injection of bevacizumab or triamcinolone. The 
data pool of the triamcinolone-treated patients with diffuse mac-
ular edema consisted of 167 participants, while that of the beva-
cizumab-treated patients comprised 59 people. Within these 
pools primarily 32 patients were randomly selected from the be-
vacizumab-treated group (32/59; 54%) and then matched with the 
patients form the triamcinolone group (32/167; 19%).
 A complete clinical examination prior to each injection was 
performed including measurement of best corrected VA with a 
numbers projecting chart (Moeller-Wedel M3000, Wedel, Ger-
many), slit lamp examination, tonometry and measurement of 
retinal thickness using OCT (Stratus OCT; Carl Zeiss Meditec, 
Jena, Germany). Prior to the first injection a fluorescein angiog-
raphy was also performed. The same examinations were repeated 
3 months following the injection of triamcinolone and 4 weeks 
after the third administration of bevacizumab (3 months after the 
first injection).
 All the patients provided written informed consent and were 
especially informed about the off-label character of the treatment 
and the potential risk of endophthalmitis and retinal detachment 
as well as the likelihood that additional treatments might be re-
quired. The Institutional Review Board had approved the present 
investigation.
 Injection Methods 
 Before injection, topical anesthesia was induced by applying 
tetracaine (1%) eye drops at least 3 times. The conjunctiva bulbi 
and the fornices were repeatedly irrigated with 1% povidone-
iodine (Betadine  , Alcon, Ft. Worth, Tex., USA). Povidone-iodine 
was also applied to the eyelid margins and the lashes, avoiding 
expression of the meibomian glands. After the application of a 
sterile drape, a lid speculum was inserted. The patients then either 
received a unilateral intravitreal injection of a 0.1-ml volume con-
taining 4 mg of triamcinolone or a 0.05-ml volume containing 
1.25 mg of bevacizmab using a sharp 27-gauge needle at a distance 
of 3.5 mm from the limbus in pseudophakic or 4.0 mm in phakic 
eyes, respectively. The needle was carefully removed using a ster-
ile cotton applicator to prevent reflux. After injection, antibiotic 
eye drops (polymyxin and neomycin) were applied for 3 days 4 
times per day. The drug was drawn under sterile conditions from 
a triamcinolone ampule or from a bevacizumab infusion bottle 
used for the systemic treatment of cancer patients by our phar-
macy department and was not diluted further. 
 Statistical Analysis 
 Only 1 eye per subject was included in the study. All the data 
were collected on an MS-Excel 2000 spreadsheet (Microsoft Cor-
poration, Redmond, Wash., USA) and analyzed using SPSS 13.0 
for Windows (SPSS Inc., Chicago, Ill., USA). For the evaluation of 
unbounded groups with dichotomously distributed variables the 
  2 and in case of multivariate variables the Mann-Whitney U test 
(MWUT) were used. When bounded groups with multivariate 
variables were compared, the Wilcoxon test (WT) was applied. 
For all results the used statistical test is given in abbreviation. For 
all statistical tests, p  ! 0.05 was considered significant. 
 Results 
 Subjects 
 Both groups of patients matched according to the 
preoperative variables evaluated ( table 1 ). The patients 
in both groups did not significantly differ considering 
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age, gender, baseline VA and CRT. In group 1 (triam-
cinolone), 29 (91%) of 32 eyes were phakic and 3 eyes 
pseudophakic, while in group 2 (bevacizumab) 26 (81%) 
of 32 eyes were phakic and 6 eyes pseudophakic (p = 
0.474;   2 test). In group 1, clinically relevant cataract for-
mation in the 29 phakic eyes at baseline was seen in 13 
cases (45%), compared to 11 cases of 26 phakic eyes 
(42%) in group 2 (p = 0.534;   2 test). After 3 months, a 
progression of cataract formation was seen in 7 (24%) of 
29 phakic eyes in group 1 and 3 (11.5%) of 26 phakic eyes 
in group 2 (p = 0.196;   2 test). All the patients had chron-
ic diffuse macular edema. No significant differences in 
blood pressure values as well as long-term blood sugar 
were observed.
 Retinal Thickness 
 The mean CRT at baseline measured by OCT was 548 
 8 185   m (range = 264–800) in group 1 and 507  8 192 
  m (range = 213–1,031) in group 2. At the 3-month con-
trol visit the patients in group 1 showed a significant 
decrease in mean CRT to 365  8 154   m (range = 192–
800, p  ! 0.001; WT;  fig. 1 ), as did those of group 2
with a significant reduction in CRT to 402  8 147   m 
(range = 192–830, p  ! 0.001; WT;  fig. 2 ). Statistical ana-
lysis showed no significant difference between both 
groups concerning CRT at baseline and 3 months and 
decrease in CRT over 3 months (p = 0.310, p = 0.204,
p = 0.128, respectively; MWUT;  fig. 3 ). The documented 
duration of macular edema in group 1 was 78.7  8 29.6 
weeks as compared to 81.9  8 31.2 weeks in group 2 (p =
0.586).
 Visual Acuity 
 At baseline, a VA of 0.72  8 0.39 logMAR in group 1 
and 0.73  8 0.39 logMAR in group 2 (p = 0.709; MWUT) 
was measured. While the patients in group 1 experienced 
a slight increase in VA following a single intravitreal tri-
amcinolone injection of on average 0.7 lines to a mean of 
0.64  8 0.40 logMAR (p = 0.066; WT) after 3 months, 
those in group 2 following 3 injections of bevacizumab 
showed almost no effect on VA with an average increase 
of 0.2 lines to a mean VA of 0.72  8 0.30 logMAR (p = 
0.948; WT;  fig. 4 ). Neither baseline VA, nor VA after 3 
months, nor the change in VA from baseline to the 
3-month control visit was statistically significantly dif-
ferent comparing both groups (p = 0.709, p = 0.212, p = 
0.115, respectively; MWUT).
 Adverse Events 
 We did not observe any adverse events that could be 
related to the injection itself or the medication used. The 
measurement of IOP showed a mean of 13.5 mm Hg pre-
operatively in group 1 and 13.3 mm Hg in group 2 com-
pared to 14.1 mm Hg after 3 months in group 1 and 13.7 
mm Hg in group 2. Of note, even in patients treated with 
triamcinolone, no relevant elevation of IOP requiring 
medical treatment was noted.
 Discussion 
 Diffuse chronic macular edema in diabetic retinopa-
thy often leads to poor prognosis concerning VA  [9] . In 
the Early Treatment Diabetic Retinopathy Study, grid la-
Table 1. Characteristics of the individual groups
Group 1
(triamcinolone)
Group 2
(bevacizumab)
p value
Gender (F/M) 13/19 17/15 0.3161
Age, years 64.688.9 64.8811.6 years 0.5452
HbA1C, %ml 7.180.80 7.080.75 0.7782
Blood pressure (systolic/diastolic) 138.0810.9/85.888.9 139.9810.6/84.489.5 0.454/0.5492
Duration of macular edema, weeks 78.7829.6 81.9831.2 0.5862
Baseline VA 20/80 (20/1,000–20/33) 20/80 (20/1,000–20/33) 0.7092
Three-month VA 20/66 (20/1,000–20/20) 20/80 (20/400–20/25) 0.2022
Baseline CRT, m 5488185 5078192 0.3102
Three-month CRT, m 3658154 4028147 0.2042
Figures are means 8 SD and values in parentheses represent ranges. 1 2 test. 2 Mann-Whitney U test.
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 Fig. 1. Scatterplot of CRT results measured by OCT in triamcin-
olone-treated eyes. 
 Fig. 2. Scatterplot of CRT results measured by OCT in bevacizu-
mab-treated eyes. 
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ser photocoagulation was recommended for patients 
with diffuse diabetic macular edema  [10] . As the effec-
tiveness concerning visual recovery varies, new thera-
peutic strategies have been proposed in order to improve 
the visual outcome.
 Intravitreally injected triamcinolone, a corticosteroid, 
has been successfully used for the therapy of chronic dif-
fuse diabetic macular edema  [4, 11–15] . Triamcinolone 
reduces VEGF expression, vascular leakage and inflam-
matory responses, all factors known to play a role in the 
pathogenesis of diabetic macular edema  [16, 17] . One ma-
jor drawback of its use is the high rate of complications, 
such as cataract formation and marked elevation of IOP 
 [18] . Supported by a number of experimental studies  [19–
24] , VEGF inhibitors have been introduced for the treat-
ment of various retinal vascular diseases. Bevacizumab is 
a humanized monoclonal antibody that binds to all sub-
forms of VEGF  [25] . Recent studies have described the 
effectiveness of bevacizumab and other anti-VEGF drugs 
to reduce chronic diabetic macular edema and increase 
VA in these eyes  [7, 26, 27] .
 Our study describes the effect of a single injection of
4 mg of triamcinolone versus 3 injections of 1.25 mg of 
bevacizumab in patients with diabetic macular edema. 
We observed a significant reduction in retinal thickness 
using both treatments, with a more pronounced effect 
seen following the treatment with triamcinolone. No sta-
tistically significant difference in the duration of macular 
edema was observed in the 2 groups. Despite this promis-
ing result, no statistically significant improvement in VA 
was seen in both groups. This result might be due to the 
composition of the selected individuals. As both drugs 
are considered ‘off-label’ for intraocular use, most eyes 
treated were cases resistant to established therapeutic ap-
proaches such as laser photocoagulation or pars plana 
vitrectomy. The patients included in this investigation 
somehow represent a ‘negative’ selection, which may in-
fluence the treatment effect both concerning changes in 
VA and CRT.
 Though eyes treated with triamcinolone showed a 
slight increase in VA, this result did just not reach statis-
tical significance (p = 0.066), which may be related to the 
relatively small sample size used in this study or the case 
selection as mentioned. However, previous studies have 
shown the positive effect of triamcinolone on VA in pa-
tients with diffuse diabetic macular edema  [4] .
 Besides the comparison of the effectiveness of mono-
therapies for diabetic macular edema as described herein, 
other investigators recently analyzed the effect of a com-
bination of a single intravitreal bevacizumab injection 
alone or in combination with intravitreal triamcinolone 
versus macular laser photocoagulation as primary treat-
ment of diabetic macular edema  [28] . They observed that 
a treatment with intravitreal bevacizumab provided a 
better visual outcome than laser photocoagulation, al-
though it was not associated with a significant decrease 
in central macular thickness. No further beneficial effect 
of intravitreal triamcinolone could be demonstrated. A 
phase II randomized clinical trial evaluating the effect of 
intravitreal bevacizumab for diabetic macular edema in 
different dosages and combination with photocoagula-
tion compared to photocoagulation alone also showed a 
beneficial effect of bevacizumab on retinal thickness and 
VA  [29] . In this study, combining focal photocoagulation 
with bevacizumab did not result in any apparent short-
term benefit or adverse outcomes.
 Due to the relatively small number of participants in-
cluded in the present study, treatment-related differences 
could not be analyzed with regard to stages of the disease, 
type of diabetes and other factors. However, the patients 
were very well matched concerning the relevant ophthal-
mologic factors we wanted to examine. Our results seem 
especially interesting with respect to the treatment re-
gime applied, with a single steroid injection showing a 
significant anatomic effect in contrast to 3 anti-VEGF in-
jections. Fewer injections may not only reduce the risk of 
adverse events such as endophthalmitis but can also be 
managed more easily by the involved personnel in offices 
and hospitals and of course help improve the patients’ 
quality of life. However, the present study aimed at an 
evaluation of the efficacy of the treatment applied and did 
not focus on potential safety concerns implicated in the 
use especially of triamcinolone, including cataract for-
mation and elevation of IOP. These points were addressed 
in former trials  [18, 30] .
 A drawback of our study is the short period of follow-
up. Further investigation is needed to evaluate the rele-
vance of additional intravitreal injections of either triam-
cinolone or bevacizumab. It would be interesting to know 
if a combined treatment of an initial injection of triam-
cinolone followed by intravitreal injections of bevaci-
zumab is efficient enough to maintain the therapeutic ef-
fect observed for triamcinolone, especially as other au-
thors recently observed no further beneficial effect of 
intravitreal triamcinolone being injected following be-
vacizumab  [28] . In addition, triamcinolone-related com-
plications may be eliminated by switching to injecting 
prednisolone sodium succinate intravitreally  [31] . A very 
recent study compared the effect of intravitreal triam-
cinolone injections (1 vs. 4 mg) and focal laser coagula-
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